Daneng Li

16.6k total citations · 5 hit papers
136 papers, 3.5k citations indexed

About

Daneng Li is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Daneng Li has authored 136 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 31 papers in Epidemiology. Recurrent topics in Daneng Li's work include Pancreatic and Hepatic Oncology Research (30 papers), Hepatocellular Carcinoma Treatment and Prognosis (28 papers) and Neuroendocrine Tumor Research Advances (27 papers). Daneng Li is often cited by papers focused on Pancreatic and Hepatic Oncology Research (30 papers), Hepatocellular Carcinoma Treatment and Prognosis (28 papers) and Neuroendocrine Tumor Research Advances (27 papers). Daneng Li collaborates with scholars based in United States, South Korea and Taiwan. Daneng Li's co-authors include Arti Hurria, Enrique Soto‐Pérez‐de‐Celis, Richard S. Finn, Wendy Verret, Philippe Merle, В. В. Бредер, Peter R. Galle, Ann‐Lii Cheng, Masatoshi Kudo and Andrew X. Zhu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Daneng Li

124 papers receiving 3.5k citations

Hit Papers

Updated efficacy and safe... 2020 2026 2022 2024 2021 2020 2021 2021 2025 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
    2021 891 citations Ann‐Lii Cheng, Peter R. Galle et al. profile →
  2. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
    2020 306 citations Richard D. Kim, Vincent Chung et al. profile →
  3. Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer
    2021 236 citations Daneng Li, Can‐Lan Sun et al. profile →
  4. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
    2021 229 citations Richard S. Finn, Peter R. Galle et al. Journal of Clinical Oncology profile →
  5. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study
    2025 26 citations Daneng Li, Shreya Badhrinarayanan et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Daneng Li 1.8k 1.1k 804 690 685 136 3.5k
Pia Österlund 3.0k 1.7× 626 0.6× 492 0.6× 1.0k 1.5× 961 1.4× 96 4.2k
Antoine Brouquet 2.1k 1.2× 1.6k 1.5× 1.8k 2.2× 632 0.9× 356 0.5× 88 3.6k
Nicholas N. Nissen 977 0.5× 904 0.8× 1.0k 1.3× 380 0.6× 1.4k 2.0× 128 3.2k
Carmine Pinto 2.3k 1.3× 150 0.1× 1.2k 1.5× 1.5k 2.1× 117 0.2× 263 3.7k
Alessio Cortellini 1.1k 0.6× 226 0.2× 158 0.2× 426 0.6× 222 0.3× 130 1.7k
Christopher J.M. Williams 975 0.5× 119 0.1× 744 0.9× 324 0.5× 838 1.2× 60 2.5k
Steven C. Cunningham 2.0k 1.1× 294 0.3× 2.4k 3.0× 1.6k 2.3× 513 0.7× 97 3.9k
Yacine Merrouche 1.7k 1.0× 138 0.1× 289 0.4× 578 0.8× 161 0.2× 103 2.5k
Vincent Lam 1.1k 0.6× 1.0k 0.9× 1.4k 1.7× 731 1.1× 450 0.7× 148 2.9k
Desmond Yip 1.6k 0.9× 321 0.3× 498 0.6× 938 1.4× 262 0.4× 162 2.9k

Countries citing papers authored by Daneng Li

Since Specialization
Citations

This map shows the geographic impact of Daneng Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daneng Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daneng Li more than expected).

Fields of papers citing papers by Daneng Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daneng Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daneng Li. The network helps show where Daneng Li may publish in the future.

Co-authorship network of co-authors of Daneng Li

This figure shows the co-authorship network connecting the top 25 collaborators of Daneng Li. A scholar is included among the top collaborators of Daneng Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daneng Li. Daneng Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abou‐Alfa, Ghassan K., Mohamed Bouattour, Ann‐Lii Cheng, et al.. (2024). Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS4190–TPS4190. 4 indexed citations
2.
Hamilton, Ashley, Robin Kate Kelley, Daneng Li, et al.. (2024). ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 42(16_suppl). TPS2675–TPS2675. 2 indexed citations
3.
4.
Heumann, Thatcher, Mark Yarchoan, Jiayun Lu, et al.. (2024). A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.. Journal of Clinical Oncology. 42(16_suppl). 4017–4017. 3 indexed citations
5.
Badhrinarayanan, Shreya, et al.. (2024). IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma. Future Oncology. 20(28). 2049–2057. 13 indexed citations
6.
Finn, Richard S., Peter R. Galle, Michel Ducreux, et al.. (2024). Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150. Liver Cancer. 13(6). 1–14. 12 indexed citations
7.
Soto‐Pérez‐de‐Celis, Enrique, William Dale, Vani Katheria, et al.. (2024). Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial. Cancer. 130(17). 3000–3010. 13 indexed citations
8.
Mahuron, Kelly M., et al.. (2024). Liver Resection for Gastroenteropancreatic Neuroendocrine Tumors with Extrahepatic Disease. Journal of Clinical Medicine. 13(17). 4983–4983.
9.
Li, Daneng, Christiana Crook, Vincent Chung, et al.. (2024). Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases. Future Oncology. 20(33). 2521–2531.
10.
11.
Hope, Thomas A., Samuel A. Mehr, Michael J. Morris, et al.. (2023). ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA. Endocrine Abstracts. 1 indexed citations
12.
Madoff, David C., Nadine Abi‐Jaoudeh, Lipika Goyal, et al.. (2022). An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma. The Oncologist. 27(10). 884–891. 9 indexed citations
13.
Li, Daneng, Can‐Lan Sun, Rebecca Allen, et al.. (2022). Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers. The Oncologist. 27(1). e37–e44. 3 indexed citations
14.
Li, Daneng, Han Chong Toh, Philippe Merle, et al.. (2022). Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. Liver Cancer. 11(6). 558–571. 18 indexed citations
15.
Kim, Dae Won, Youngchul Kim, Bence Kővári, et al.. (2022). Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer. European Journal of Cancer. 176. 171–180. 7 indexed citations
16.
Thornblade, Lucas W., Paul Wong, Daneng Li, et al.. (2021). Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma. Cancers. 13(16). 4062–4062. 7 indexed citations
17.
Nguyen, Andrew H., Michael P. O’Leary, James P. De Andrade, et al.. (2021). Presentation and survival of gastro-entero-pancreatic neuroendocrine tumors in young adults versus older patients. The American Journal of Surgery. 223(5). 939–944. 3 indexed citations
18.
Liu, Jennifer, Simran Padam, Daneng Li, et al.. (2020). Strategies to Improve Participation of Older Adults in Cancer Research. Journal of Clinical Medicine. 9(5). 1571–1571. 17 indexed citations
19.
Chen, Bihong T., Sunita K. Patel, Ningrong Ye, et al.. (2019). Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study. eScholarship (California Digital Library). 1 indexed citations
20.
Hurria, Arti, Daneng Li, Kurt Hansen, et al.. (2009). Distress in Older Patients With Cancer. Journal of Clinical Oncology. 27(26). 4346–4351. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pia Österlund Breakdown of academic impact, for papers by Antoine Brouquet Breakdown of academic impact, for papers by Nicholas N. Nissen Breakdown of academic impact, for papers by Carmine Pinto Breakdown of academic impact, for papers by Alessio Cortellini Breakdown of academic impact, for papers by Christopher J.M. Williams Breakdown of academic impact, for papers by Steven C. Cunningham Breakdown of academic impact, for papers by Yacine Merrouche Breakdown of academic impact, for papers by Vincent Lam Breakdown of academic impact, for papers by Desmond Yip
Rankless by CCL
2026